

# RUNAWAY

## AFFORDABLE PRICES FOR REAL CURES



*RunawayRx*, a project of the California Association of Health Plans, highlights noteworthy articles and information on the acceleration of prescription drug pricing.

The Alliance of Community Health Plans (ACHP) today released an [infographic](#) highlighting the rising costs of treating rheumatoid arthritis (RA), a disease that affects 1.3 million Americans. The annual cost of treating RA in the U.S. is expected to increase by almost 50 percent from 2013 to 2020. Today's news is yet another reminder of why we need to shed light on how drugs are priced to ensure that they are affordable and accessible.

### Rheumatoid Arthritis Drug Prices Skyrocket

March 30, 2016




"A new infographic from the Alliance of Community Health Plans (ACHP) highlights rising drug prices for the 1.3 million Americans suffering from rheumatoid arthritis (RA). Left untreated, RA can cause permanent disability, but high costs may leave drugs out of reach for many patients.

Key findings include:

- The annual cost of treating RA in the U.S. is expected to increase by almost 50 percent from 2013 to 2020, and is expected to reach over \$9 billion.
- The RA drug Enbrel now costs more than \$4,000 for a 30-day supply, an 80 percent increase since 2013.
- The cost of RA drugs can exceed more than \$1 million over the course of a lifetime.
- Sixty percent of people with inadequately treated RA are unable to work 10 years after onset."

**"The cost of taking RA drugs can exceed \$1 million over the course of an individual's lifetime."**



Read more: <http://bit.ly/1omcxO8>

###

The California Association of Health Plans' RunawayRx project sheds light on the acceleration of prescription drug pricing and how it impacts health care affordability, encouraging a route toward sustainable pricing. For more information, please visit [www.RunawayRx.org](http://www.RunawayRx.org) or follow us on Twitter at [@Runaway Rx](https://twitter.com/RunawayRx).